The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1220
ISSUE1220
October 24, 2005
Montelukast (Singulair) for Perennial Allergic Rhinitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Montelukast (Singulair) for Perennial Allergic Rhinitis
October 24, 2005 (Issue: 1220)
Montelukast (Singulair - Merck) is an oral cysteinyl leukotriene D4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.